Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 7, 2015, Pages 7967-7977

  Kim, Min Ju ^a   Jung, Woo Hee ^b   Koo, Ja Seung ^b  

^a Gachon University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Androgen receptor; Breast cancer; Sarcosine

Indexed keywords

ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; GLYCINE METHYLTRANSFERASE; GNMT PROTEIN, HUMAN; PIPOX PROTEIN, HUMAN; SARCOSINE; SARCOSINE DEHYDROGENASE; SARCOSINE OXIDASE; SARDH PROTEIN, HUMAN; TUMOR MARKER;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMISTRY; DEFICIENCY; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; PATHOLOGY; STROMA CELL; TIME FACTOR; TISSUE MICROARRAY;

ADULT; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; GLYCINE N-METHYLTRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; SARCOSINE; SARCOSINE DEHYDROGENASE; SARCOSINE OXIDASE; STROMAL CELLS; TIME FACTORS; TISSUE ARRAY ANALYSIS;

EID: 85012969648     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C and Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-914.
2. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A and Chinnaiyan AM. The role of sarcosine metabolism in prostate cancer progression. Neoplasia 2013; 15: 491-501.
3. Baum CE, Price DK and Figg WD. Sarcosine as a potential prostate cancer biomarker and therapeutic target. Cancer Biol Ther 2010; 9: 341-342.
4. Kuenen-Boumeester V, Van der Kwast TH, Claassen CC, Look MP, Liem GS, Klijn JG and Henzen-Logmans SC. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1996; 32A: 1560-1565.
5. Riva C, Dainese E, Caprara G, Rocca PC, Massarelli G, Tot T, Capella C and Eusebi V. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch 2005; 447: 695-700.
6. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M and Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24: 4660-4671.
7. Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, Ingster O, Vabres P, Caux F, de Reynies A, Iggo R, Sevenet N, Bonnet F and Longy M. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 2010; 12: R63.
8. Dahl M, Bouchelouche P, Kramer-Marek G, Capala J, Nordling J and Bouchelouche K. Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Mol Biol Rep 2011; 38: 4237-4243.
9. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, WittliffJL and WolffAC. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone recep tors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
10. WolffAC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G and Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
11. Elston CW and Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
12. Won KY, Kim GY, Kim YW, Song JY and Lim SJ. Clinicopathologic correlation of beclin-1 and bcl-2 expression in human breast cancer. Hum Pathol 2010; 41: 107-112.
13. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, Kristiansen G and Jung K. Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 2011; 185: 706-711.
14. Lee CM, Yen CH, Tzeng TY, Huang YZ, Chou KH, Chang TJ and Arthur Chen YM. Androgen response element of the glycine N-methy-ltransferase gene is located in the coding region of its first exon. Biosci Rep 2013; 33: e00070.